These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 8504018)

  • 41. Tamoxifen prophylaxis in breast cancer.
    Love RR
    Oncology (Williston Park); 1992 Jul; 6(7):33-8; discussion 38-40, 43. PubMed ID: 1386239
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of the TEAM Greek sub-study.
    Markopoulos C; Polychronis A; Zobolas V; Xepapadakis G; Papadiamantis J; Koukouras D; Lappas H; Gogas H
    Breast Cancer Res Treat; 2005 Sep; 93(1):61-6. PubMed ID: 16184460
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Administration of long-term tamoxifen therapy modifies the plasma lipoprotein-lipid concentration and lipid transfer protein I activity in postmenopausal women with breast cancer.
    Wasan KM; Ramaswamy M; Haley J; Dunn BP
    J Pharm Sci; 1997 Jul; 86(7):876-9. PubMed ID: 9232532
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Extended breast cancer treatment with an aromatase inhibitor (Letrozole) after tamoxifen: why, who and how long?
    Kaufmann M; Rody A
    Eur J Obstet Gynecol Reprod Biol; 2006 Jun; 126(2):146-54. PubMed ID: 16621229
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tamoxifen metabolism and its effect on endocrine treatment of breast cancer.
    Briest S; Stearns V
    Clin Adv Hematol Oncol; 2009 Mar; 7(3):185-92. PubMed ID: 19398943
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
    Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
    Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The curability of breast cancer and the treatment of advanced disease.
    Guarneri V; Conte PF
    Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S149-61. PubMed ID: 15107948
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Should tamoxifen be used in breast cancer prevention?
    Kramer R; Brown P
    Drug Saf; 2004; 27(13):979-89. PubMed ID: 15471505
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Estrogen replacement therapy for breast cancer patients.
    Colditz GA
    Oncology (Williston Park); 1997 Oct; 11(10):1491-4, 1497; discussion 1498, 1501. PubMed ID: 9348555
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The role of selective estrogen receptor modulators on breast cancer: from tamoxifen to raloxifene.
    Lee WL; Cheng MH; Chao HT; Wang PH
    Taiwan J Obstet Gynecol; 2008 Mar; 47(1):24-31. PubMed ID: 18400579
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Endometrial changes with chronic tamoxifen use.
    Loret de Mola JR
    Curr Opin Obstet Gynecol; 1997 Jun; 9(3):160-4. PubMed ID: 9263698
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cardiovascular safety profiles of aromatase inhibitors : a comparative review.
    Nabholtz JM; Gligorov J
    Drug Saf; 2006; 29(9):785-801. PubMed ID: 16944964
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The use of early adjuvant aromatase inhibitor therapy: contributions from the BIG 1-98 letrozole trial.
    Forbes JF
    Semin Oncol; 2006 Apr; 33(2 Suppl 7):S2-7. PubMed ID: 16730270
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial.
    Jakesz R; Jonat W; Gnant M; Mittlboeck M; Greil R; Tausch C; Hilfrich J; Kwasny W; Menzel C; Samonigg H; Seifert M; Gademann G; Kaufmann M; Wolfgang J;
    Lancet; 2005 Aug 6-12; 366(9484):455-62. PubMed ID: 16084253
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tamoxifen and breast cancer--from palliation to prevention.
    Rich SE
    Cancer Nurs; 1993 Oct; 16(5):341-6. PubMed ID: 7505194
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tamoxifen effects on menopause--associated risk factors and symptoms.
    Benshushan A; Brzezinski A
    Obstet Gynecol Surv; 1999 Apr; 54(4):272-8. PubMed ID: 10198932
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Overview from the International Conference on Long-Term Tamoxifen Therapy for Breast Cancer.
    Jordan VC
    J Natl Cancer Inst; 1992 Feb; 84(4):231-4. PubMed ID: 1346404
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of tamoxifen on spinal bone density in women with breast cancer.
    Turken S; Siris E; Seldin D; Flaster E; Hyman G; Lindsay R
    J Natl Cancer Inst; 1989 Jul; 81(14):1086-8. PubMed ID: 2738937
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The incidence of hepatocellular carcinoma in US white women with breast cancer after the introduction of tamoxifen in 1977.
    Mühlemann K; Cook LS; Weiss NS
    Breast Cancer Res Treat; 1994; 30(2):201-4. PubMed ID: 7949218
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tamoxifen in the prevention of breast cancer. Are the risks likely to outweigh the benefits?
    O'Brien M; Powles TJ
    Drug Saf; 1994 Jan; 10(1):1-4. PubMed ID: 8136084
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.